Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
China
Chongqing Cancer Hospital, Chongqing, Chongqing Municipality Fujian Cancer Hospital, Fuzhou, Fujian Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong Anyang Cancer Hospital, Anyang, Henan Henan Cancer Hospital, Zhengzhou, Henan Hubei Cancer Hospital, Wuhan, Hubei Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Hunan Cancer Hospital, Changsha, Hunan Jinan Central Hospital, Jinan, Shandong Qilu Hospital Shangdong University, Jinan, Shandong Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality Second Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi Zhejiang Cancer Hospital, Hangzhou, Zhejiang First Hospital Affiliated to Wenzhou Medical University, Wenzhou, Zhejiang